KLK3 and prostate cancer: Specifically, since the United States Preventive Services Task Force (USPSTF) recommended against routine PSA screening in 2012, the incidence of advanced prostate cancer has increased by 4% annually and incidence of de novo metastatic disease has increased by 6% annually.31